Cutler Group LP Travere Therapeutics, Inc. Call Options Transaction History

Cutler Group LP

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 07, 2023	SELL	$7.64 - $17.25 $16,044 - $36,225	-2,100 Reduced 70.0%	900 $0
Q2 2023 Jul 18, 2023	BUY	$15.3 - $22.61 $45,900 - $67,830	3,000 New	3,000 $0
Q1 2022 Apr 14, 2022	BUY	$23.61 - $30.6 $151,104 - $195,840	6,400 Added 581.82%	7,500 $10,000
Q4 2021 Jan 18, 2022	SELL	$24.34 - $31.17 $19,472 - $24,936	-800 Reduced 42.11%	1,100 $1,000
Q3 2021 Oct 26, 2021	BUY	$12.98 - $25.03 $24,662 - $47,557	1,900 New	1,900 $2,000

192

84.5M

776K

900K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.12B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.